Summit Therapeutics cites positive HARMONi-2 overall survival data
Summit Therapeutics said partner Akeso presented HARMONi-2 data showing ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive non-small-cell lung cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.